Ipragliflozin/sitagliptin - Astellas Pharma/MSD KK

Drug Profile

Ipragliflozin/sitagliptin - Astellas Pharma/MSD KK

Alternative Names: Ipragliflozin L-proline/sitagliptin; MK 0431J; Sitagliptin/ipragliflozin; Sitagliptin/ipragliflozin L-proline

Latest Information Update: 01 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma; MSD KK
  • Developer Astellas Pharma; Kotobuki Pharmaceutical; MSD KK
  • Class Antihyperglycaemics; Glucosides; Pyrazines; Small molecules; Thiophenes; Triazoles
  • Mechanism of Action CD26 antigen inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus

Most Recent Events

  • 26 May 2017 Chemical structure information added
  • 01 May 2017 Preregistration for Type-2 diabetes mellitus in Japan (PO)
  • 15 Apr 2015 Early research in Type-2 diabetes mellitus in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top